Skip to Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Cancer Diagnosis Program
Contact NExT
Show menu
Search this site
Last Updated: 07/21/14

Magdalena Thurin, Ph.D.

Program Director

Magdalena Thurin’s, Ph.D. major focus has been on validation of biomarkers for clinical application in cancer with specific interest on the cutting-edge areas of molecular markers in melanoma and the immune response markers for prognosis and prediction of response to treatment. Prior to joining NCI in 2001 she conducted research at The Wistar Institute of Anatomy and Biology in Philadelphia focusing on structural and functional characterization of carbohydrate antigens and application for diagnosis including Sialyl-Lewis A (SA-Le A) that became a diagnostic test for pancreatic and colon cancer (CA 19-9). She has published over 70 research and review papers, she is on editorial board for several journals and recently edited a book “Molecular diagnostics for melanoma”. At CDP she is actively pursuing her interest in organizing national and international meetings, working groups and resources to promote marker validation that will impact the diagnosis, prognosis and treatment of cancer.